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Background: Hydroxyethyl starch (HES) is reportedly associated with an increased risk of renal failure 
and death when used for fluid resuscitation in critically ill patients. HES can be used during therapeutic 
leukocytapheresis (TL) procedures to enhance cell separation. The purpose of this study was to evaluate 
the occurrence of adverse events associated with HES during TL procedures. Study design and methods: 
We performed a retrospective review of patients who underwent TL with and without HES in the period 
2009 – 2013 at six academic medical institutions. Results: A difference-in-difference (DID) regression 
analysis was used to estimate the average change before and after TL in selected outcomes in the HES 
group relative to the average change in the non-HES group. Selected outcomes included serum creatinine, 
estimated glomerular filtration rate (eGFR), and white blood cell count (WBC). One hundred and ninety 
five patients who underwent 278 TL procedures were studied. We found no statistically significant 
differences in serum creatinine levels and eGFR at day 1 and day 7 after TL procedure between patients 
who received and those who did not receive HES. The rate of adverse events, and overall and early 
mortality were similar in both groups. Patients with AML who received HES had greater WBC reduction 
when HES was used. Additionally, patients who received HES had improvement in pulmonary 
leukostasis symptoms. Conclusion: HES used at low doses during TL procedures, was not associated with 
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Patients with acute leukemia presenting with hyperleukocytosis (white blood cell count > 50,000 – 
100,000/mL) are at risk for developing symptomatic leukostasis, disseminated intravascular coagulopathy 
and tumor lysis syndrome. Hyperleukocytosis has been associated with poor prognosis and increased 
early mortality. 
1
 Therapeutic leukocytapheresis (TL) is a procedure intended to remove circulating 
leukemic cells. Although it is still controversial whether TL has impact on early mortality, TL can be 
considered as a coadjuvant therapeutic modality for patients presenting with rapidly rising white blood 
cell count (WBC) or with signs and symptoms suggestive of leukostasis. 
2,3
 Hydroxyethyl starch (HES) 
can be used during TL to enhance separation between leukocytes and red cells during centrifugation 
resulting in more efficient white cell removal.  
HES is derived from plant starches and consists of large starch molecules that can be added to saline to 
generate a colloidal solution. Due to its volume-expanding properties, HES has been used for volume 
replacement in critically ill and surgical patients. Recent studies evaluating HES as volume replacement 
demonstrated that critically ill patients, especially those with sepsis, had an increased risk of renal failure 
compared to patients who did not receive HES. 
4-17
 These results prompted the FDA to issue a "black box 
warning" about the dose dependent risks associated with its use, including an increased risk of mortality 
and renal injury in critically ill patients, and excess bleeding in patients undergoing open heart surgery 
associated with cardiopulmonary bypass. 
18
 These results and “black box warning” have resulted in the 
banning of the use of HES in some European countries, and the limited use of HES in cases of 
hypovolemia not responding to crystalloid administration with a recommendation that HES should be 
used at the lowest effective dose for the shortest period of time. 
19
 
However, there are no definitive studies which have directly attributed use of HES with renal dysfunction 
or increased mortality during TL. The American Society for Apheresis (ASFA) commented on the risks 
of the use of HES, and recommended avoiding the use of HES in critically ill patients, patients with renal 
insufficiency, patients with sepsis, and patients at risk of bleeding who are undergoing apheresis 
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procedures and has recommended its use be limited to situations where the benefits of performing the 
indicated procedure outweigh the risks. 
20
 
The aim of this study was to assess whether the use of HES during TL resulted in an increased rate of 
mortality, adverse events, and acute kidney injury as compared to patients undergoing TL without HES.  
 
Methods 
We performed a retrospective chart review of patients who underwent TL with and without HES in the 
period 2009 – 2013 at six academic institutions. The academic institutions were selected based on their 
experience with at least 5 TL procedures per year, and its geographical location representing different 
areas of the country (Northwest, Northeast, Midwest, and South). IRB approval was obtained from all 
participating institutions. Only adult patients with myeloid or lymphoid malignancies were included. Data 
collected included age, gender, diagnosis, exposure to nephrotoxic medications within and after 7 days of 
the first and last TL procedure, chemotherapy treatment, indications for TL, procedure characteristics, and 
adverse events associated with the procedure. Serum creatinine levels, estimated glomerular filtration rate 
(eGFR), and the need for renal replacement therapy (RRT) were evaluated before and after each 
procedure, and up to seven days after the last TL procedure. Given the improvement in creatinine levels 
after the first TL in both groups, it was not possible to use the RIFLE (Risk, Injury, Failure, Loss of 
kidney function, and End-stage kidney disease) score to classify the renal injury. The severity of 
symptoms attributed to leukostasis was characterized using the Novotny score (Table 1), and patients 
were evaluated before and within 24 hours of each TL procedure. 
21
 The Novotny score attributes the 
probability of leukostasis syndrome based on severity of symptoms: 0 (leukostasis not present, no 
symptoms) to 3 (leukostasis highly probable, severe symptoms), and was calculated before and after each 
procedure.  
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The WBC count of the collection bag was not available to determine the efficiency of the collection, so 
the following formula [(WBC Pre procedure – WBC Post procedure)/WBC Pre procedure] was used to 
assess cell depletion. At the two major institutions, samples were drawn immediately after the procedure 
was completed and the device was disconnected.  The central line or peripheral IV (depending upon 
patient access) was flushed, and after wasting an appropriate volume of blood, a sample for CBC was 
collected and sent for testing.    
HES was used routinely at two institutions for all leukocytapheresis except when there was severely 
compromised renal function, history of reactions to HES, or history of allergy to corn (source of HES).  
The rationale for this use is based upon the published literature demonstrating greater yields in 
granulocyte collections with the use of HES and extrapolating this to leukocyte reductions. 
22
 HES was 
not routinely used at the other four institutions. Only one of these institutions would consider to use HES 
based on the cell type to be removed (i.e., myeloid malignancies), and apheresis attending physician’s 
preferences. The mononuclear cell program (MNC) was the preferred mode across institutions used for 
procedures except when the peripheral smear demonstrated a more mature cell phenotype.  The 
polymorphonuclear cell program (PMN) was utilized for chronic myelogenous/myelomonocytic 
leukemia, or in the presence of an acute leukemia arising from a pre-existing chronic myelogenous 
leukemia. The preference for MNC is that in most acute leukemias, the size/density of the blasts will be in 
the range of a mononuclear cell and not a granulocyte.   
Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic 
data capture tools hosted at Children's National Medical Center. REDCap is a secure, web-based 
application designed to support data capture for research studies, providing 1) an intuitive interface for 
validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated 
export procedures for seamless data downloads to common statistical packages; and 4) procedures for 
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We used a quasi-experimental method known as difference-in-difference (DID). 
24,25
  The basic DID 
approach is as follows. First, the mean pre vs. post difference in outcome in the HES group (labeled 
difference 1) and in the non-HES group (labeled difference 2) are calculated. Then, difference 2 is 
subtracted from difference 1.  The result, DID = difference 1– difference 2, is the pre vs. post difference 
in outcome in the HES group net of the pre vs. post difference in outcome in the non-HES group. For 
example, if the HES group showed a 10% decrease from day 0 to day 1 and the non-HES group showed a 
15% decrease in the same period of time, the DID estimate would yield an actual net increase in the HES 
group of 5% [-10% - (-15%)], compared to the non-HES group. 
To improve the precision of the estimates, minimize bias, and obtain a reliable estimate of the statistical 
significance, we applied DID in a linear regression framework instead of calculating the differences 
arithmetically. We ran separate models for each outcome (dependent variable of the regression) [serum 
creatinine, WBC, eGFR, RRT, and symptomatic improvement (pulmonary and neurologic severity 
scores)]. The serum creatinine, WBC, and eGFR outcomes were log-transformed to mitigate the effect of 
outliers and also to estimate approximate percentage, rather than absolute, changes in outcome. Being 
dichotomous and ordinal variables respectively, RTT and the clinical outcomes were used untransformed. 
The right-hand side of the DID equation includes only four variables:  a subject-level indicator (also 
known as individual fixed effect), an indicator taking 1 if the observation is post-treatment and 0 
otherwise, and an indicator taking 1 if the observation is post-treatment and comes from the HES group. 
This is a standard specification for a DID model. 
24
 The main coefficient of interest is the associated to the 
latter variable, since it measures the change in outcomes for treatment observations during the post-
treatment period. A positive and statistically significant coefficient for observations that corresponds to 
both post-treatment and HES group can be interpreted as an outcome increase caused by the 
administration of HES. Conversely, a negative and statistically significant coefficient can be interpreted 
as an outcome decrease caused by the administration of HES. The DID design removes all observed and 
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unobserved time-invariant heterogeneity (demographics, number of procedures, days of admission, ICU 
admission, diagnosis, etc.) across patients. The p-values associated with t-tests reported in the regression 
were based on heteroskedastic-robust standard errors.  
Differences between the HES and non-HES groups for mortality (early and overall) and adverse events 
were analyzed using t-tests. All statistical analyses were performed in STATA 8 (StataCorp, College 
Station, TX). A p value <0.05 was considered significant for all statistical tests performed. 
 
Results 
Patients and procedure characteristics 
Descriptive analyses show that patients’ characteristics were overall similar in both groups, with 
significant differences in race, FAB (French-American-British) leukemia classification, and disease 
severity (Table 2). Patients in the non-HES group had at baseline more severe neurologic and pulmonary 
leukostasis symptoms (Table 2).  
TL procedure characteristics are described in Table 3. All procedures were done using COBE Spectra 
(TerumoBCT, Lakewood, CO). The average number of procedures in the HES and non-HES group were 
1.3 and 1.4 respectively (p=0.368). One hundred thirty six patients (69.7%) underwent one TL procedure, 
46 (23.6%) patients underwent 2 procedures, 10 (5.3%) underwent 3 procedures, and 3 patients (1.4%) 
required 4 procedures. The HES formulation used across institutions was hetastarch (6% in 0.9% sodium 
chloride, 600/0.7) (Hespan, DuPont Cirtical Care, Inc, Waukegan, IL) 
 
Outcomes  
Outcome trends show that renal function, as measured by serum creatinine levels and eGFR, and WBC 
counts improved throughout the 7 day period after first TL procedure in both groups (Figure 1). 
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Descriptive analyses indicate that renal function, need for RRT, WBC count, mortality and adverse events 
were similar in both groups on days 0, 1, and 7 (Table 4). The rate of adverse events was similar in both 
groups, with a total of 4 TL related adverse events in the HES group (2 mild citrate toxicity, 1 probable 
volume overload, and 1 patient with a history of seizure disorder, who developed seizures incidental to 
the TL procedure) and 8 events in the non-HES group (4 citrate toxicity, 1 venous access related, 1 low 
level bleeding from the line, 1 vasovagal reaction) (Table 4). 
The DID regression analyses showed that percent changes in serum creatinine levels and eGFR between 
the two groups were not significant (Table 5). However, white blood cell reduction was significantly 
greater on day 1 in the HES group when compared to the non-HES group (DID = -26.4% p=0.002). On 
day 7, there were no differences in WBC between the two groups (Table 5). The DID regression analysis 
also showed that the percent change in the pulmonary severity score was significantly more favorable 
after TL for patients who received HES compared to patients who did not received HES (DID=-0.25; 
p=0.013) (Figure 2) (Table 5). The advantage for the HES group was not seen with neurologic symptoms 
(DID=-0.050 p=0.727).  
When separate models for AML and CMML/CML were run, the WBC reduction was significantly greater 
on day 1 in the HES group when compared to the non-HES group (DID=-26.3% p=0.006) for AML, and 
higher, but not statistically significant, for CMML/CML (DID=-27.5% p=0.170).  
The fraction of cells removed [(WBC Pre procedure – WBC Post procedure)/WBC Pre procedure] was 
statistically larger in patients with diagnosis of AML when using HES (59% +/- 20%), compared to a 
similar cohort of patients not using HES (47% +/- 19%, p= 0.001). For patients with the diagnosis of 
CML/CMML, the fraction of cells removed when using HES and not using HES was 41%+/- 33% and 
28% +/- 25%, respectively (p=0.345). Patients with lymphoid malignancies had similar fraction of cells 
removed when using HES and no HES, 60% +/- 23 and 46% +/- 23%, respectively (p=0.175). 
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Studies using HES as a volume expander in critically ill patients admitted to the ICU, as well as  surgical 
patients, have concluded that HES is associated with increased renal failure and mortality, particularly in 
septic patients. 
6
 We found no increase in renal toxicity, mortality, or adverse events in 70 patients 
undergoing TL using HES as compared to 125 patients who underwent TL without HES. The lack of 
nephrotoxicity in our group of patients is not likely related to differences in HES formulation or patients’ 
underlying medical condition.  
Starch formulations have significant differences in metabolism and elimination, mainly determined by the 
molar substitution. The molar substitution represents the amount of hydroxyethyl residues attached to the 
anhydrous glucose particles, and the level of substitution determines the solubility of the starch in water 
and degradation rate. HES formulations are named based on the molar substitution (MS) as hetastarch 
(MS = 0.7), hexastarch (MS = 0.6), pentastarch (MS = 0.5) and tetrastarch (MS = 0.4), and the lower the 
substitution the higher the degradation and smaller the retention in circulation. In other words, the more 
highly substituted HES formulation (i.e., hetastarch), the greater the accumulation compared to a less 
substituted HES (i.e., tetrastarch). HES concentration, molecular weight, molar substitution, and pattern 
of substitution, determine the accumulation rate and the maximum daily dose. 
26
 The maximum 
recommended daily dose of 6% HES is 1,500 mL or not to exceed 20 mL/Kg. 
26,27
 
Most studies evaluating renal function and mortality in septic and critically ill patients receiving HES 
used tetrastarches, which have a better elimination profile compared to hetastarch. Whether these 
different formulations affect renal outcomes is uncertain. 
6
 However, we did not observe adverse events 
associated to HES accumulation. In studies in which nephrotoxicity was observed, the HES dose ranged 
from 1.7 L in 24 hours to 70 mL/kg with median duration of 14 days. 
7,28
. Our patient population received 
a much smaller dose with an average of 9.08 mL/kg, which is within the limits of the maximum 
recommended dose. In addition, HES was only used in the context of the TL procedure and not for 
volume expansion.  
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A recent meta-analysis concluded that septic patients are at higher risk of renal injury when compared to 
surgical patients, and the use of HES could contribute to the increased risk of renal failure by unknown 
mechanisms. It was speculated that changes in the plasma viscosity or reticuloendothelial system function 
could contribute to this increase in toxicity. 
6
 Patients with hematological malignancies are at increased 
risk of renal failure as evidenced by the increased creatinine in our cohort of patients and previous reports.  
29,30
 Our findings suggest that the use of HES did not worsen the renal outcomes. Furthermore, the renal 
function improved in the HES and non-HES groups. It is important to mention that patients with renal 
dysfunction were not excluded from the use of HES during the procedure 
The use of HES has been reported to improve WBC collection yield. 
31
 We observed a significant WBC 
reduction in patients receiving HES. When we separately evaluated AML and CML/CMML patients, 
patients with AML had greater WBC reduction when HES was used. An important possible bias to 
mention is that the majority of patients receiving HES came from 2 institutions and differences in 
chemotherapy regimens could also contribute to WBC after TL treatment. Timing of the sample 
collection to determine the WBC count may differ across institutions as well. The lack of statistical 
significance in the CML/CMML groups’ WBC removal, could be partially explained by the relatively 
small sample size (n=23).  An alternative explanation is that CML and CMML represent chronic 
leukemia with significant tumor involvement of the spleen. It is possible that mobilization of WBCs from 
the patients’ enlarged spleens resulted in a failure to reduce the patients’ circulating WBC mass. 
Furthermore, the formula we used to calculate the efficiency does not account for the WBC count in the 
bag, and as a result, the removal of cells is underestimated when rapid mobilization occurs from the 
spleen. We also observed that patients who received HES had a significant improvement of pulmonary 
symptoms when compared to patients who did not receive HES. The short and long term mortality was 
similar in both groups, so the clinical implications of this symptomatic improvement are uncertain. 
HES is also commonly used during granulocyte collections from healthy donors, who typically receive 
steroids and/or granulocyte colony stimulating factor (GCSF) to increase granulocyte yields. 
Page 10 of 23
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901 1 (434) 964-4100
Transfusion












Approximately 450-475 mL of HES is used per procedure. Renal function is not routinely evaluated in 
these patients. Adverse events associated with the use of HES during these donations are limited to 
pruritus (up to 6% in one series) and very rare allergic reactions (<0.1% of collections). 
32
 
 For therapeutic plasma exchange procedures, HES, alone or in combinations with albumin replacement, 
has been used for patients who do not wish not to receive blood products with an acceptable safety 
profile. 
33-36
 Chronic HES exposure (130 L within 20 months) can lead to an acquired lysosomal storage 
disease with symptomatic, massive, diffuse tissue infiltration of HES-laden foamy macrophages. 
37,38
 
Kidney failure after chronic TPE using low dose (60 g) HES combined with albumin as replacement fluid 
has also been described. 
39
 
HES has been associated with adverse events including allergic reactions that ranged in severity from 
mild to anaphylactic reactions. A study that evaluated colloid plasma substitutes at 31 hospitals in 
Germany, including 16,405 HES infusions, described a calculated incidence of severe anaphylactoid 
reactions (shock, cardiac or respiratory distress) of 0.006%. 
40
 We did not observed allergic reactions in 
our cohort of patients. 
Dose dependent coagulation abnormalities and risk of bleeding were also described in patients receiving 
HES. 
41
 Low doses of HES are associated with minor abnormalities of coagulation test results that are 
usually not clinically significant. 
42
 Massive amounts of HES, > 25% blood volume, have been studied in 
dogs and were associated with bleeding partially attributed to dilution effect.  
This study has several weaknesses, including its retrospective nature, inability to calculate collection 
efficiency of the TL procedures, possible differences in chemotherapy regimens, and site bias. Although 
there were 6 institutions included in this study, only 2 of these institutions accounted for 82% of TL 
procedures where HES was used. These weaknesses prevent drawing definite conclusions, but the results 
of this study suggest that HES, when used in low doses, does not result in renal injury, improves 
pulmonary status of patients undergoing TL, and can improve leukodepletion efficiency. 
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In summary, although there is extensive evidence that fluid resuscitation using HES can result in renal 
impairment and increase mortality, these adverse effects were not seen in adult patients undergoing TL 
with HES. Further studies are required to confirm the finding of improvement of pulmonary leukostasis 
syndrome using HES during TL.  
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Table 1. Probability of leukostasis based on severity of neurologic and respiratory symptoms. The 
Novotny score. 
Score Probability of 
l ukostasis 
Severity of symptoms Respiratory 
Symptoms 
Neurologic symptoms 
0 Not present No limitations No limitations No limitations 
 
1 Possible Slight limitations Mild limitations, 
comfortable at rest 
Mild tinnitus, headache, 
dizziness 
 








Severe limitations Dyspnea at rest, 
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Table 2. Patients’ characteristics at baseline 







Age, years (mean) 56 56.3 55.9 0.886 
Male sex, n (%) 122 (62.6) 44 (62.8) 78 (62.4) 0.95 
Race, n (%) 
White 155 (78.9) 61 (87.1) 94 (74.2) 0.034 
Black 19 (9.8) 8 (11.0) 11 (8.8) 0.567 
Unknown or mixed 16 (8.2) 1 (1) 15 (12) 0.009 
Native Hawaiian or other Pacific Islander 1 (1) 0 1 (1) 0.288 
Asian 1 (1)  0 1 (1) 0.288 
American Indian or Alaska Native 1 (1) 0 1 (1) 0.288 
Diagnosis, n (%)         
AML 143 (73) 52 (74) 91 (73) 0.823 
CML 18 (9) 7 (10) 11 (9) 0.783 
CMML 5 (3) 3 (4) 2 (2) 0.257 
Other 29 (14) 8 (11)  21 (17) 0.314 
AML FAB Classification, n (%)   53 116   
M0 6 (3.5) 2 (4) 4 (3) 0.916 
M1 11 (6.5) 7 (13) 4 (3) 0.017 
M2 6 (3.5) 5 (9) 1 (0.8) 0.005 
M3 3 (1.8) 0 3 (2) 0.24 
M4 31 (18.3) 6 (11) 25 (21) 0.112 
M5 42 (24.8) 20 (38) 22 (19) 0.009 
M6 0 0 0 0 
M7 1 (0.6) 0 1 (0.8) 0.501 
Non applicable 69 (40.8) 13 (24) 56 (48) 0.003 
Baseline, day 0         
Hematocrit, %  24.2 24.6 23.6 0.293 
Platelet, thousand/µL 82.95 86.7 79.2 0.674 
WBC, thousand/µL 210 204.3 216.3 0.581 
Blast % 61.5 59.3 63.7 0.39 
Serum creatinine, mg/dL 1.44 1.49 1.39 0.511 
eGFR, mL/min/BSA 53.8 50.4 57.2 0.103 
Total days of admission 23.15 24.4 21.9 0.341 
     
Severity score, Neurologic % (n=192)         
0 42 50 0.011 
1 8 20 0.351 
2 10 22 0.505 
3 10 30 0.092 
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Severity score, Respiratory % (n=193) 
0 31 26 0.001 
1 8 19 0.442 
2 13 19 0.577 
3 18 59 0.002 
Note: AML: acute myeloid leukemia, CML: chronic myeloid leukemia, CMML: chronic myelomonocytic 
leukemia, FAB: French-American-British, eGFR: estimated glomerular filtration rate, BSA: body surface 
area.  
Others include: 12 acute lymphoblastic leukemia (ALL), 4 pre-B cell ALL, 3 T cell ALL, 2 primary 
myelofibrosis, 1 chronic lymphocytic leukemia, 1 myeloid neoplasm with mixed myeloproliferative and 
myelodysplastic features with excess blasts (14% in marrow) and marked bone marrow fibrosis, 1 B cell 
lymphoblastic leukemia, 1 lymphoid blast crisis of CML, 1 blast phase CML with mixed phenotype, 1 
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Table 3. Characteristics of therapeutic leukocytapheresis procedures 
Apheresis procedures HES, N = 91 No HES, N = 187 
Average number of procedures 1.3 1.4 
Presence of symptomatic leukostasis 69 (75.8) 166 (88.8) 
Mode MNC 74 (81.3) 186 (99) 
Mode PMN 17 (18.7) 1 (1) 
Collection target 
2 x Blood volume 4 (4.3) 177 (94.6) 
3 Hours 57 (62.6) 1 (0.5) 
Cell count < 50 K 21 (23) 0 
10 liters 9 (9.9) 9 (4.8) 
Average HES dose per Kg 9.08 mL/Kg NA 
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Figure 1. Outcome trends from day 0 [before therapeutic leukocytapheresis (TL)] through day 7. A) 
Mean serum creatinine levels, B) mean estimated glomerular filtration rate (eGFR), and C) mean white 
blood cell count (WBC) before and 7 days after the first TL procedure. Mean serum creatinine levels and 






































































C) HES No HES
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Table 4. Descriptive statistics, outcome variables. Mean serum creatinine levels, eGFR, WBC, need for 
RRT and mortality (early and overall) were not significantly different when compare HES and No HES 
groups at three different time points (day 0, day 1 day 7). 
 




Serum creatinine mg/dL, day 0 1.49 1.39 0.511 
Serum creatinine mg/dL, day 1 1.37 1.36 0.972 
Serum creatinine mg/dL, day 7 1.04 1.01 0.805 
eGFR mL/min/BSA, day 0 50.4 57.2 0.103 
eGFR mL/min/BSA, day 1 51.15 50.2 0.744 
eGFR mL/min/BSA, day 7 57.91 67.26 0.071 
RRT before first procedure, n 
(%) 
3 (4.3) 1 (0.8) 0.101 
RRT after first procedure, n (%) 7 (10) 7 (5.6) 0.256 
WBC thousand/µL, day 0 204 216 0.581 
WBC thousand/µL, day 1 102.01 127.5 0.188 
WBC thousand/µL, day 7 12.8 20.27 0.546 
Overall mortality, n (%) 12 (18) 32 (26) 0.266 
Early mortality, n (%) 7 (10) 22 (18) 0.115 
Adverse events, n (%) 4 (5.7) 8 (6.4) 0.849 
Note: eGFR: estimated glomerular filtration rate; RRT renal replacement therapy; WBC: white blood cell 
count   
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Figure 2. Change in leukostasis symptoms classified using the Novotny scores before and after 
leukocytapheresis (TL) procedures. A) Neurologic symptoms: there is a positive delta (increment) 
proportion of patients with score 0 (less symptoms) after TL, and a negative delta (decrease) for severity 
scores 1, 2, and 3 (interpreted as improvement), in HES and No HES groups. B) Respiratory symptoms: 
there is a positive delta (increment) proportion of patients with severity score 0 (less symptoms) in both 
groups, and with severity score 1 only for HES group. There is a negative delta (decrease) proportion of 
patients with severity score 2 in both groups, and with severity score 3 for the HES group. There is null 
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Table 5. Difference in difference (DID) regression estimates for selected outcomes 
Variable Change (p) 
Serum creatinine, day 0 to day 1, % change -1.1% (p=0.696) 
Serum creatinine, day 0 to day 7, % change 8.8% (p=0.262) 
eGFR, day 0 to day 1, % change 4.7% (p=0.108) 
eGFR, day 0 to day 7, % change -4.8% (p=0.519) 
WBC, day 0 to day 1, % change -26.4% (p=0.002) 
WBC, day 0 to day 7, % change -20.5% (p=0.511) 
Severity score, pulmonary, before and after % change -0.25 (p=0.013) 
Severity score, neurologic, before and after % change -0.050 (p=0.727) 
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